New triple therapy targets tough leukemia

NCT ID NCT06445959

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 5 times

Summary

This study tests a combination of three drugs—olutasidenib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) that has a specific IDH1 gene mutation. The goal is to find a safe and effective dose for those whose cancer has returned or not responded to treatment, as well as for newly diagnosed patients who cannot tolerate intensive chemotherapy. The trial will monitor side effects and early signs of benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olutasidenib, decitabine, and venetoclax
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific genetic subtype of AML, potentially improving remission rates.
What could go wrong: This is an early-phase trial (Phase 1b/2) with only 78 participants, so safety and dosing are still being established. The combination may cause significant side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUTANT IDH1 INHIBITOR OLUTASIDENIB

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Roswell Park
RECRUITING

Buffalo, New York, 14263, United States
The University of Kansas Medical Center
RECRUITING

Westwood, Kansas, 66205, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.